A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs

Abstract

This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs Phase: PHASE1 Status: NOT_YET_RECRUITING Conditions: Small Cell Lung Cancer (SCLC ); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Gastroenteropancreatic NEC (GEP NEC); Neuroendocrine Prostate Cancer (NEPC) Interventions: ML261

Keywords

Sources